Early diagnosis of amyloid heart disease is of utmost importance as the presence and especially the severity of cardiac involvement generally drives the prognosis of affected subjects and plays a major role in determining the intensity of specific treatment, namely in AL amyloidosis. The management of...
A significant proportion of patients with familial amyloidosis have clinical involvement of the heart, and heart failure is almost always the presenting feature of senile systemic amyloidosis. The severity of the cardiac symptoms and the response to treatment vary depending upon the type of amyloid ...
Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient In addition, the company will discuss the progress on its lead programmes: NEOD001, a monoclonal antibody targeting AL and AA amyloid for the potential treatment of amyloidosis; PRX002, a monoclonal antibody ta...
PATIENTS: 36 patients with cardiac amyloid heart disease, of whom 12 had familial and 24 had primary AL amyloidosis. RESULTS: Familial and AL ... S.,W.,Dubrey,... - 《Heart Official Journal of the British Cardiac Society》 被引量: 231发表: 1997年 The contribution of genotypes at the ...
A nonhereditary form of systemic amyloidosis associated with wild-type transthyretin causes heart involvement predominantly in elderly men (systemic senile amyloidosis, or SSA). However, hereditary transthyretin-related amyloidosis (ATTR) is the most frequent form of familial systemic amyloidosis, a group...
Background:Individually, heart failure (HF) and Alzheimer's disease (AD) are severe threats to population health, and their potential coexistence is an alarming prospect. In addition to sharing analogous epidemiological and genetic profiles, biochemical characteristics, and common triggers, the authors...
et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement. 11, 249–257.e1 (2015). Article PubMed Google Scholar Rembach, A. et al. Changes in plasma amyloid β in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement...
Future work will aim to further the development of small-molecule-based ATF6-modulating compounds for the treatment of systemic amyloid diseases. Together, these experiments challenge the long-held notion that ATTR amyloidosis livers are unaffected by the disease. Through the use of our iPSC-based ...
Simon Sharpe3, Pharhad Eli Arslan1, Per Westermark4, Jeffrey N. Higaki5, Ronald Torres5, José Tapia5 & Avijit Chakrabartty1 ®Wild-type and mutant transthyretin (TTR) can misfold and deposit in the heart, peripheral nerves, and other sites causing amyloid disease. ...
(https://www.decode.com); Genetic and Environmental Risk in AD (GERAD); International Genomics of Alzheimer's Disease Consortium (IGAP); European AD Initiative (EADI); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE); Alzheimer's Disease Exome Sequencing-France (ADES-FR)...